221 (PB101) – Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers
Home » 221 (PB101) – Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers
2022
Pearson AT, Muzaffar J, Bellile E, Worden FP, Chung CH, Rosenberg A, Vokes E, Fidler MJ, Brenner JC, Zhai Y, Fu T, Winkler R, Swiecicki P. 221 (PB101) – Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers. Eur J Cancer. vol. 174(suppl 1):, pp. S79-S80. [2022 EORTC-NCI-AACR poster presentation]-S79-S80. [2022 EORTC-NCI-AACR poster presentation], View